Infergen, or consensus interferon, is a bio-optimized, selective and highly potent type 1 interferon alpha. It is currently indicated as monotherapy for the treatment of adult patients suffering from chronic hepatitis C viral infections with compensated liver disease and is dosed three times per week.
Donald Kerrish, Three River’s president and CEO, said: “Adding Infergen to our growing portfolio is very exciting. This purchase is only a beginning for Three Rivers’s continuous strategy to increase its product offerings through product acquisition and internal product development of pharmaceutical therapies.”